2021
DOI: 10.1097/mpa.0000000000001858
|View full text |Cite
|
Sign up to set email alerts
|

Osteoclast-Like Giant Cell Tumors of the Pancreas

Abstract: ObjectivesThis study sought to better characterize patient characteristics, treatment options, and outcomes for osteoclast-like giant cell carcinoma of the pancreas, a rare subtype of pancreatic adenocarcinoma.MethodsThis is a retrospective study of all patients with osteoclast-like giant cell carcinoma of pancreatic origin treated at Mayo Clinic from 2000 to present. Baseline patient characteristics, treatment modalities utilized, and outcomes were compiled. Overall survival (OS) and progression-free survival… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 22 publications
1
0
0
Order By: Relevance
“…The opinion given in the WHO 2019 Digestive System Tumors Volume is that patients may survive for 1 year or more ( 9 ). The survival time of UCOGCP reported in most existing literature also shows similar or better results ( 30 , 41 , 69 ). Based on the data analysis of UCP patients in the National Cancer Database (NCDB), the median survival time of UCOGCP patients was 24.8 months and the estimate 3-year and 5-year survival rates were 42.54% and 39.01%, respectively ( 70 ).…”
Section: Prognosissupporting
confidence: 59%
“…The opinion given in the WHO 2019 Digestive System Tumors Volume is that patients may survive for 1 year or more ( 9 ). The survival time of UCOGCP reported in most existing literature also shows similar or better results ( 30 , 41 , 69 ). Based on the data analysis of UCP patients in the National Cancer Database (NCDB), the median survival time of UCOGCP patients was 24.8 months and the estimate 3-year and 5-year survival rates were 42.54% and 39.01%, respectively ( 70 ).…”
Section: Prognosissupporting
confidence: 59%